09:00

Strategic Approaches to ADC Bioanalysis: Navigating In Vivo Biotransformation and Incurred Sample Challenges

Daiichi Sankyo，Senior Director，Ling He

1）Complex muti-domain modalities like ADCs warrants tailored PK and immunogenicity assay strategies to inform drug  development

2）Case examples for that incurred samples may behave differently from control samples due to in vivo biotransformation  or patient-specific matrix factors

3）Practical frameworks and mitigation strategies for resolving incurred sample-specific assay issues

09:30

Development of First-in-class, Clinical Stage ADC EBC-129 for Solid Malignancies

EDDC，Director, Asset Lead，Veronica Diermayr

1）EBC-129 is an ADC that targets the conserved N256-glycosylation site in CEACAM5 & CEACAM6 linked to MMAE as a  payload

2）The EBC-129 antigen is highest expressed in GI cancers (70-100% have ≥20% expression at 2+/3+) as well as lung cancer  (55%)

3）In the current Ph1/1B trial (focused on GI cancers) EBC-129 showed promising clinical efficacyin pancreatic ductal  adenocarcinomas and gastro-oesophageal adenocarcinomas with a very manageable safety profile

10:00

Manufacturing of mAb and ADC: current solutions and addressing concerns around extract-ables and leachables

Cytiva，Scientist，Konstantin Artemenko

10:30

Coffee Break & Networking

10:50

VelaVigo: An Innovative Biotech Focusing on FIC and BIC Multi-Specific ADC and TCE

VelaVigo，CEO，Jing Li 

1）Biologics Innovation & Industry Impact

2）FIC/BIC Multi-Specific Biologics with Internal Proprietary Target Mining and Drug Discovery Engine

3）Pipeline Progress & Strategic Collaborations

11:20

Computational pathology to guide use of ADCs

AstraZeneca，Senior Director，Markus Schick

1）Leveraging computational pathology to revolutionize the discovery and delivery of precise biomarkers.

2）Developing quantitative continuous scoring (QCS), an innovative AI-based platform that enables in-depth interrogation of complex target and tumor biology driving the efficacy of antibody-drug conjugates (ADCs).

3）Exploring novel computational pathology-based biomarkers to predict clinical outcomes in patients treated with ADCs

11:50

Broad-Spectrum Efficacy of CEACAM6-Targeted ADC with BBT Protein Degrader in Solid Cancer Models

Eisai，Scientist，Hiroyuki Kogai

12:20

Panel Discussion: ADC Deals in Asia

Moderator：

SDIC Venture Capital, Director，Jing Zhong

Guests：

Innolake Biopharm, COO，Robert Chen

Roche，Director of Pharma Partnering，Kyle Chen

09:00

T Cell Therapy: A Tumor-Agnostic Patient-Centric Strategy

MD Anderson Cancer Center, Professor, Cassian Yee

09:30

Tackling the bottleneck of cell based therapy, transformation from ex vivo to in vivo gene editing by open innovation

Nanjing IASO Biotechnology，Chief Innovation and Investment Officer，Xavier Xie

10:00

From Autologous CAR-T to Allo Cell Therapy

Tikva Allocell，CEO and Founder，Ivan Horak MD, FACP

1）Challenges of autologous CART

2）Next generation Allo cell therapies

3）From cancer treatment to autoimmune diseases

10:30

Fully Human Fab and VHH Synthetic Library Enable CAR-T Antibody Discovery

Constream Bio，CEO，Frank Tao

10:40

Coffee Break & Networking
 

10:50

Next-Generation TIL Therapy -- Challenges and Strategies

Biosyngen, Senior Scientist, Mingyu Liu

11:20

11:50

12:20

15:50

Enhancing Therapeutic Impact: Integrating Co-stimulatory Signaling in TGR-T Therapies for Solid Tumors

Imgen BioSciences，President，Wendell Yang

1）Unique advantages of TCR-T cell therapy

2）Potential for enhancing TCR-T therapy efficacythrough integration with co-stimulatory signalingapproaches

3）Strategic considerations for incorporating co-stimu-latory signaling, with a focus on molecular designs ofTCR-based therapies, such as TCR-CAR-T

16:20

Versatile Engineering Platform for Anti-Cadherin 17 CAR-T/NK Cell-based Cancer Therapy

Arbele Bio，CTO，Tong Wong

1）CDH17 as a promising target for cancer immunotherapy

2）Arbele’s proprietary mRNA CAR-T/NK platform

3）Preclinical development of ARB001

16:50

Non-Viral BaAb Armed-T Therapy

CytoArm，CEO，Kuo-Hsiang Chuang

1）The Armed-T platform provides a novelmethod for T cell therapies, highlighting keyadvantages such as high purity, virus-free pro.cesses, and quick large-scale production

2）Armed Tcells exhibit diverse features thathelp overcome the immunosuppressive tumomicroenvironment

3）The Armed-T platform is designed to behighly adaptable, enabling it to target a broadrange of cancers

17:20

Development of Bispecific Extracellular Vesicles for Cancer Immunotherapy

National University of Singapore，Associate Professor，Le Thi Nguyet Minh

1）Development of bispecific extracellular vesicles (BEVs) derived from natural red blood cell for immune activation  through dual targeting of CD3 on T cells and tumor antigens on cancer cells

2）Enhanced potency of BEVs over free antibodies, as demonstrated by stronger T cell activation, increased pro-inflamma-  tory cytokine secretion, and reduced toxicity risks at lower therapeutic concentrations

3）Clinical translation potential of the BEV platform, supported by robust anti-tumor efficacyin immunosuppressive lung and pancreatic cancer models, favorable safety in non-human primates